{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:59:52Z","timestamp":1782129592403,"version":"3.54.5"},"reference-count":24,"publisher":"Korean Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011027","name":"Kowa Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011027","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novo Nordisk Pharma and Sumitomo Pharma Co. Ltd."},{"name":"Ichiro Sakuma received research grants from Kowa Pharmaceutical Co. Ltd."},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"name":"Life Scan Japan"},{"name":"Taisho Pharmaceutical Co. Ltd."},{"name":"Astellas Pharma Inc."},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chugai Pharmaceutical Co. Ltd."},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Otsuka Pharmaceutical Co. Ltd."},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alexion Inc."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Teijin Pharma Ltd."},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chugai Pharmaceutical Co. Ltd."},{"name":"Astellas Pharma Inc."},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UCB Japan Co. Ltd."},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kyowa Kirin Co. Ltd"},{"name":"Taisho Pharmaceutical Co. Ltd."},{"DOI":"10.13039\/100004325","name":"AstraZeneca plc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical and Biological Laboratories Co. Ltd."},{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2024,5,31]]},"abstract":"<jats:p>Background: Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal function of diabetic subjects with or without CKD in a real-world clinical setting.Methods: We performed a sub-analysis of data collected during a multi-center, prospective, observational study of the effects of pemafibrate on lipid metabolism in subjects with type 2 diabetes mellitus complicated by hypertriglyceridemia (the PARM-T2D study). The participants were allocated to add pemafibrate to their existing regimen (ADD-ON), switch from their existing fibrate to pemafibrate (SWITCH), or continue conventional therapy (CTRL). The changes in estimated glomerular filtration rate (eGFR) over 52 weeks were compared among these groups as well as among subgroups created according to CKD status.Results: Data for 520 participants (ADD-ON, &lt;i&gt;n&lt;\/i&gt;=166; SWITCH, &lt;i&gt;n&lt;\/i&gt;=96; CTRL, &lt;i&gt;n&lt;\/i&gt;=258) were analyzed. Of them, 56.7% had CKD. The eGFR increased only in the SWITCH group, and this trend was also present in the CKD subgroup (&lt;i&gt;P&lt;\/i&gt;&lt;0.001). On the other hand, eGFR was not affected by switching in participants with severe renal dysfunction (G3b or G4) and\/or macroalbuminuria. Multivariate analysis showed that being older and a switch from fenofibrate were associated with elevation in eGFR (both &lt;i&gt;P&lt;\/i&gt;&lt;0.05).Conclusion: A switch to pemafibrate may be associated with an elevation in eGFR, but to a lesser extent in patients with poor renal function.<\/jats:p>","DOI":"10.4093\/dmj.2023.0370","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T07:48:35Z","timestamp":1709192915000},"page":"473-481","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease"],"prefix":"10.4093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5525-7290","authenticated-orcid":true,"given":"Rimi","family":"Izumihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-221X","authenticated-orcid":true,"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuno","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yanagiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Miya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on Behalf of the PARM-T2D Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","first-page":"1832","volume-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","author":"Retnakaran","year":"2006"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-15-8"},{"key":"ref3","first-page":"2032","volume-title":"Diabetic kidney disease: challenges, progress, and possibilities","author":"Alicic","year":"2017"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1951-1"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"ref6","first-page":"1923","volume-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","author":"Das Pradhan","year":"2022"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110091"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.11.004"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030768"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2524-2"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000064083"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.129197"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.08.008"},{"key":"ref15","first-page":"393","volume-title":"Peroxisome proliferator-activated receptor alpha target genes","author":"Mandard","year":"2004"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00677.2004"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.08.012"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.02.013"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej20-0808"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.111.261388"},{"key":"ref21","first-page":"882","volume-title":"The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study","author":"Scuteri","year":"2005"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00903-0"},{"key":"ref23","first-page":"143","volume-title":"What is the role of statistics in medical science?: a critical essay","author":"Hayashi","year":"1992"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2018.04.475"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.e-dmj.org\/upload\/pdf\/dmj-2023-0370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2023.0370","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.e-dmj.org\/upload\/pdf\/dmj-2023-0370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T04:07:20Z","timestamp":1716523640000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2023.0370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2023.0370","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"2023-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}